In addition to O-phosphorylation, O-linked modifications of serine and threonine by ␤-N-acetyl-D-glucosamine (GlcNAc) may regulate muscle contractile function. This study assessed the potential role of O-GlcNAcylation in cardiac muscle contractile activation. To identify specific sites of O-GlcNAcylation in cardiac myofilament proteins, a recently developed methodology based on GalNAz-biotin labeling followed by dithiothreitol replacement and light chromatography/tandem mass spectrometry site mapping was adopted. Thirty-two O-GlcNAcylated peptides from cardiac myofilaments were identified on cardiac myosin heavy chain, actin, myosin light chains, and troponin I. To assess the potential physiological role of the GlcNAc, force-[Ca
D iabetes mellitus is a risk factor for the development of heart failure, 1 and abnormal glucose metabolism may contribute directly to depressed cardiac function. Studies in humans and animal models of diabetes mellitus have demonstrated abnormal myofilament function 2 and impaired excitation-contraction coupling, 3, 4 which may depress myocardial function. Posttranslational modifications of myofilament proteins regulate cardiac function and phosphorylation of myofilament proteins may result in functional abnormalities in heart failure. [5] [6] [7] In addition to O-linked phosphorylation of serine (Ser) and threonine (Thr) residues of proteins, dynamic O-linked ␤-N-acetyl-D-glucosamine (O-GlcNAc) modifications can also regulate protein structure and function, 8 and interplay between O-GlcNAcylation and O-phosphorylation may have an important role in cellular function. 9, 10 Although recent studies have suggested that O-linked modifications of Ser/Thr by GlcNAc could be involved in the regulation of myofilament Ca 2ϩ activation properties in skeletal muscle, [11] [12] [13] cardiac myofilament proteins have not been examined for this modification. Conversely, recent studies on isolated myocytes have directly associated diabetic cardiac dysfunction with increased levels of O-GlcNAcylation of cardiac proteins (Ͼ50kD), albeit the specific proteins and residues modified remained unknown. 9 Those studies prompted us to verify the hypothesis that modification of cardiac myofilament proteins by O-GlcNAc could also regulate cardiac contractile function.
Materials and Methods

Mass Spectrometric Identification of O-GlcNAc-Modified Proteins
To label the specific sites (further details are in the online data supplement, available at http://circres.ahajournals.org), GlcNAcmodified peptides were labeled with GalNAz-biotin and enriched by avidin chromatography, and then dithiothreitol (DTT) was used to replace the GlcNAc-GalNAz-biotin by ␤-elimination and Michael addition (BEMAD) as previously described. 14 
Isolated Skinned Fiber Studies
For skinned fiber studies, cardiac trabeculae were isolated and mounted as previously described. 5 
Immunoblots
Myofilament proteins were isolated as previously described, 15 with minor modifications. To determine the global GlcNAc modifications of myofilament proteins, a pan-GlcNAc antibody (CTD 110.6, Covance) was used as previously described. 16 To assess cardiac troponin I (cTnI) phosphorylation, a phospho-TnI (Ser23/Ser24) antibody (Cell Signaling, Danvers, Mass) was used as previously described. 5 
Results and Discussion
Myofilament Proteins Are Modified by O-GlcNAc
With the enrichment and BEMAD experiments described, mass spectrometric (MS) data demonstrated that at baseline cardiac myofilament proteins are O-GlcNAcylated at the specific amino acid residues noted in Table I in the online data supplement. Thirty-two O-GlcNAcylated peptides from cardiac myofilaments were identified: 21 from cardiac myosin heavy chain, 6 from ␣-sarcomeric actin, 2 from myosin light chain 1, 1 from myosin light chain 2, and 1 from troponin I. As a control for specificity, in a parallel preparation treated extensively with ␤-N-acetyl-hexosaminidase to remove O-GlcNAc before enrichment, no modified sites were Figure 1A and 1B. The DTT modification on Ser54 of cardiac actin was confirmed by the observation of multiple matched ion pairs that contain the DTT mass ( Figure 1A ). We also identified O-GlcNAcylation at Ser150 of TnI ( Figure  1B ). Interestingly, Ser150 is also phosphorylated by p21-activated kinase 3, a modification that increases calcium sensitivity. 17 This is the first report to define specific sites of O-linked GlcNAc of cardiac myofilament proteins. Although studies of skeletal muscle suggested GlcNAcylation of myosin heavy chain, actin, and myosin light chains, they did not define specific sites. 11 Most of the newly identified O-GlcNAcylated sites in cardiac myofilaments were not previously described as phosphorylated, with the exception of cTnI Ser150 and MLC2 at Ser15. Interestingly, the O-GlcNAc targets in MLC1 at Thr 93/Thr164 are different from phosphorylation sites at Thr69 and Ser 200, previously found in pharmacological preconditioning. 18 
GlcNAc-Desensitized Myofilaments to Calcium Without Altering Phosphorylation of TnI Ser23/24
To characterize the effects of O-linked GlcNAc in cardiac muscle steady-state force- [Ca 2ϩ ] relationships were studied in freshly skinned rat trabeculae. Baseline force-[Ca 2ϩ ] relationships were established in individual trabeculae, thereafter the trabeculae were washed in relaxing solution and exposed to either 200 mmol/L Glycerol (nϭ5), 200 mmol/L GlcNAc (nϭ7) or 5 mmol/L GlcNAc (nϭ3) in a relaxing solution. After 1 hour incubation at room temperature, force-[Ca 2ϩ ] relationships were determined. As shown in Figure 2A through 2C, a significant desensitization of the force-calcium relationship was observed in GlcNAc but not glycerol exposed trabeculae (pCa 50 1.81Ϯ0.13 mol/L for Control versus 3.83Ϯ0.44 mol/L for 200 mmol/L GlcNAc, nϭ7, Pϭ0.001, pCa50 1.86Ϯ0.51 mol/L for Control versus 3.24Ϯ0.44 mol/L for 5 mmol/L GlcNAc, nϭ3, PϽ0.05), whereas maximal force (F max ) and Hill coefficient (n) were not significantly modified. Notably, despite washing out GlcNAc and bathing for 1 hour with fresh relaxing solution, pCa50 did not return to basal levels (data not shown). These results indicate that the changes observed are not dependent on simple chemical artifacts or osmotic alterations reflected on myofilament lattice, the later usually sensitize rather than desensitize myofilaments. 19 Brief (Ϸ5 to 10 minutes) skinning in relaxing solution containing 1% Triton X-100 allows permeation of membranous system to calcium but preserves endogenous O-GlcNAc transferase activity. Skinned trabeculae showed immuno-reactivity to anti-O-GlcNAc transferase antibody and possessed metabolically active enzymes to incorporate [ 3 H]-GlcNAc into proteins of a wide range of 20 It is well known that PKA phosphorylation of TnI Ser 23/24 results in desensitization of the myofilaments to calcium. 21 Therefore we sought to exclude the possibility that GlcNAc exposure altered calcium sensitivity by modifying phosphorylation levels at cTnI Ser23/Ser24. Using an antibody specific for phosphorylation at Ser23/Ser24 we concluded that GlcNAc exposure had no effects on phosphorylation at Ser23/Ser24 of TnI ( Figure 2D ). It is plausible that a balance between O-GlcNAcylation and O-Phosphorylation at cTnI Ser150 and MLC2 Ser15 could have an important role in regulating cardiac contractility; however that was not directly investigated in this work. Taken together, these results strongly suggest that excess of GlcNAc levels in myofilaments from cardiac trabeculae decreases cardiac myofilament sensitivity to calcium, through a mechanism that does not involve TnI phosphorylation at Ser23/Ser24.
Exposure to GlcNAc Alters Cardiac Myofilament O-GlcNAcylation Pattern
To further assess the effects of acute GlcNAc exposure, fresh cardiac myofilament preparations were examined using the pan-specific O-GlcNAc antibody CTD 110.6. We determined the pattern of myofilament GlcNAcylation at baseline ( Figure  3A) . Proteins of a wide range of molecular weight, from Ϸ15 to Ϸ250 kDa were detected ( Figure 3A, lane 1) . Next, the effects of preincubating myofilament preparations in vitro with 0.2 mol/L GlcNAc on GlcNAcylation pattern were studied ( Figure 3A, lane 2) . Interestingly, GlcNAc exposure was associated with an increase in actin GlcNAcylation levels (from 27.6Ϯ4.2% to 35.1Ϯ2.36%, nϭ4, PϽ0.05, Figure 3B ). There were no significant differences in total signal level by densitometry after GlcNAc exposure. Treatment with PNGaseF (an enzyme that removes specifically N-linked glycans) did not significantly alter the staining pattern or content (data not shown), suggesting that most of the observed GlcNAcylation signal derived from O-linked GlcNAc. To explore the relevance of this phenomenon in relevant pathophysiologic models, GlcNAcylation pattern was examined in similar fashion on cardiac myofilament preparations from ob/ob mice and streptozotocin treated rats and their respective controls. Interestingly, ob/ob mice and STZ rats myofilaments showed an increase in actin GlcNAcylation levels (36.4Ϯ7.8% to 53.2Ϯ2.1%, nϭ3 versus nϭ3 *PϽ0.05 for ob/ob mice and 42.7Ϯ2% to 50.9Ϯ3.2%, nϭ3 versus nϭ4 *PϽ0.05 for STZ rats, supplemental Figure I ). Current evidence shows that acute enhancement of O-GlcNAcylation of specific myocardial protein targets may have cardioprotective effects 22 ; however, it is also plausible that chronic increase of O-GlcNAcylation may impair cardiac function in diabetic cardiomyopathy. 9, 23 These data suggest that O-GlcNAcylation of actin can be increased by GlcNAc exposure in vitro and that this phenomenon is also present in vivo in relevant models of diabetes mellitus. O-GlcNAcylation of actin and/or other myofilament proteins may be responsible for the decreased submaximal force development observed in diabetes mellitus; however, increased ROS production and other factors may contribute. 24 The O-GlcNAc antibody may not be sensitive enough to detect subtle changes in GlcNAcylation of other myofilament proteins. Exposure to GlcNAc alters cardiac myofilament O-GlcNAcylation pattern. Myofilament preparations were exposed to relaxing solution only (control) or containing 0.2 mol/L GlcNAc for 1 hour at room temperature. Densitometry analysis of the blots was performed using ImageJ software. A, GlcNAcylation pattern of control and GlcNAc exposed myofilaments with respective densitometry plots (top) and actin signals as loading control (bottom). B, Contribution of actin peak to total GlcNAcylation staining pattern, where actin peak is increased from 27.6Ϯ4.2% to 35.1Ϯ2.36% (nϭ4). *PϽ0.05.
In summary, this study has identified specific sites of O-GlcNAc modification of myofilament proteins and provides evidence that this posttranslational modifications can regulate myofilament function. This also raises the possibility that there could be a dynamic interaction between O-GlcNAc and O-phosphate modification of MLC2 and TnI as is well described for other proteins. 8 Further studies of how O-GlcNAcylation of myofilament proteins regulates cardiac contractility may reveal novel and useful therapeutic targets in heart failure, especially in diabetic cardiomyopathy.
